射频消融治疗良性甲状腺结节:10年经验
这项回顾性研究纳入2007年3月至2010年12月连续接受射频消融治疗的症状性良性无功能甲状腺结节的421例患者(456个结节),随访至2022年8月,中位随访90个月。2年、5年和≥10年平均体积缩小率分别为81%、90%和94%,总体再生长率为12%(53/456),初始体积≥20 mL的结节再生长风险显著高于<10 mL者(HR 2.315,95%CI 1.183-4.530,p=0.014)。作者结论为射频消融安全有效,但需定期随访以监测再生长和延迟手术。
要点
- 中位随访90个月,结节平均体积缩小率2年81%、5年90%、≥10年94%。
- 总体再生长率12%(53/456),初始体积≥20 mL者再生长风险显著高于<10 mL者(HR 2.315)。
- 延迟手术率6%(26/421),总体并发症率2.4%(10/421),无操作相关死亡或长期并发症。
核心结论
- 射频消融治疗良性甲状腺结节安全有效,长期随访体积缩小率高。
- 由于消融结节可能再生长且部分患者需延迟手术,初次成功后应定期随访。
研究设计与样本
- 回顾性研究,纳入2007年3月至2010年12月连续接受射频消融治疗的症状性良性无功能甲状腺结节的421例患者(456个结节)。
- 中位随访90个月(四分位距24-143个月),随访至2022年8月,于1、6、12个月及之后每年随访并计算体积缩小率。
- 采用Kaplan-Meier法评估再生长累积发生率,并作单变量和多变量Cox回归分析再生长危险因素。
主要发现
- 平均体积缩小率2年为81%、5年为90%、≥10年为94%。
- 总体再生长率12%(53/456),其中33个结节重复射频消融、4个手术、16个继续观察。
- 初始体积≥20 mL的结节再生长风险显著高于初始体积<10 mL者(HR 2.315,95%CI 1.183-4.530,p=0.014,多变量Cox回归)。
- 延迟手术率6%(26/421),原因包括再生长和/或持续症状(n=4)或新发现甲状腺肿瘤(n=22,良性1例、恶性21例)。
- 总体并发症率2.4%(10/421),无操作相关死亡或长期并发症。
关键数值与推荐
- 再生长按三种已发表标准评估。
- 体积缩小率2年81%、5年90%、≥10年94%。
- 初始体积≥20 mL组再生长风险HR 2.315(95%CI 1.183-4.530,p=0.014),对照为初始体积<10 mL组。
- 总体再生长率12%(53/456),延迟手术率6%(26/421),并发症率2.4%(10/421)。
临床怎么用
- 作者认为射频消融治疗良性甲状腺结节安全有效,长期随访体积缩小率高。
- 作者认为初次成功后应定期随访,因消融结节可能再生长且部分患者需延迟手术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Longer follow-up after radiofrequency ablation (RFA) of benign thyroid nodules is needed to understand regrowth and other causes of delayed surgery and long-term complications. Methods: This retrospective study included consecutive patients treated with RFA for symptomatic benign nonfunctioning thyroid nodules between March 2007 and December 2010. RFA was performed according to the standard protocol. We followed up patients at 1, 6, and 12 months, then yearly, until August 2022, and calculated the volume reduction ratio (VRR) at each follow-up. We assessed the incidence of regrowth according to three published criteria, delayed surgery, and complications. The Kaplan-Meier method was used to evaluate the cumulative incidence of regrowth, and univariable and multivariable Cox regression analyses were performed to identify risk factors for regrowth. Results: This study included 421 patients (mean age, 47 ± 13 years; 372 women) with 456 nodules (mean volume, 21 ± 23 mL). The median follow-up period was 90 months (interquartile range, 24-143 months). The mean VRR was 81% at 2 years, 90% at 5 years, and 94% at ≥10 years. Overall regrowth was noted in 12% (53/456) of nodules and was treated with repeat RFA (n = 33) or surgery (n = 4) or left under observation (n = 16). Thyroid nodules with ≥20 mL initial volume had significantly higher risk of regrowth compared with nodules with <10 mL initial volume (hazard ratio, 2.315 [95% confidence interval, 1.183-4.530]; p = 0.014 on multivariable Cox regression analysis). Delayed surgery was performed in 6% (26/421) of patients because of regrowth and/or persistent symptoms (n = 4) or newly detected thyroid tumors (n = 22), one benign and 21 malignant. The overall complication rate was 2.4% (10/421), with no procedure-related deaths or long-term complications. Conclusion: RFA is safe and effective for treating benign thyroid nodules, with a high VRR at long-term follow-up. Regular follow-up after initial success is warranted because of the possibility of regrowth of ablated nodules and the need for delayed surgery in some patients.
引用
- Park SI, Baek JH, Lee DH, et al. Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules: 10-Year Experience. Thyroid. 2024. PMID: 39041607. doi:10.1089/thy.2024.0082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。